↓ Skip to main content

Dove Medical Press

Article Metrics

The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia

Overview of attention for article published in Neuropsychiatric Disease and Treatment, August 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
43 Mendeley
Title
The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia
Published in
Neuropsychiatric Disease and Treatment, August 2015
DOI 10.2147/ndt.s86722
Pubmed ID
Authors

Bruce Wang, Chiun-Fang Chiou, Ronald Caldwell, Jung-Sun Lee, Nathan Kothandaraman, SunKyoung Lee, Jin Wang, Fan Zhang, Wesley Furnback

Abstract

Schizophrenia results in substantial health care utilization costs. Much of these costs can be attributed to health care use resulting from nonadherence to treatment, relapse, and hospitalization. The objective of this research is to further estimate the health care resource utilization costs of patients with schizophrenia in the People's Republic of China, Korea, and Malaysia with a specific focus on the reduction in hospitalization costs associated with the use of long-acting, injectable paliperidone palmitate (PP) relative to alternative treatment medications. The study focuses exclusively on the estimated reduction in hospitalization days following treatment with PP and the potential associated cost savings. Cost analysis was done using a payer's perspective and only includes direct health care costs associated with hospitalization. Localized cost data were taken from published sources, and health care utilization was estimated based on a clinical study conducted in countries in the Asia-Pacific region. People's Republic of China, Korea, and Malaysia had the highest number of patients enrolled in the clinical study, and thus were chosen for this research. Analysis looked at 12-month and 18-month periods following initial treatment with PP relative to a retrospective 12-month period utilizing alternative treatment medications. Results suggest that reductions in hospital utilization cost over 12 months may occur through the use of PP relative to alternatives-ranging from $1,991 for the People's Republic of China to $6,698 for Korea and $6,716 for Malaysia. Given the substantial costs associated with the treatment of schizophrenia both worldwide and in Asia, it is important to fully understand the costs and outcomes associated with various treatment options. In this research, we have specifically analyzed the direct health care cost savings associated with hospital utilization for patients taking PP relative to alternative treatment methods. The results suggest that reductions in hospital utilization cost were associated with PP treatment, likely largely due to increased adherence to treatment.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 43 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 21%
Researcher 8 19%
Student > Bachelor 6 14%
Student > Postgraduate 3 7%
Student > Ph. D. Student 3 7%
Other 5 12%
Unknown 9 21%
Readers by discipline Count As %
Medicine and Dentistry 9 21%
Economics, Econometrics and Finance 5 12%
Psychology 4 9%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Nursing and Health Professions 2 5%
Other 6 14%
Unknown 14 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 August 2015.
All research outputs
#15,342,608
of 22,821,814 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,781
of 2,986 outputs
Outputs of similar age
#154,510
of 264,253 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#80
of 92 outputs
Altmetric has tracked 22,821,814 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,986 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,253 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.